A citation-based method for searching scientific literature

Allison W Kurian, Antonis C Antoniou, Susan M Domchek. Am Soc Clin Oncol Educ Book 2016
Times Cited: 18







List of co-cited articles
152 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
502
55

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
Allison W Kurian, Emily E Hare, Meredith A Mills, Kerry E Kingham, Lisa McPherson, Alice S Whittemore, Valerie McGuire, Uri Ladabaum, Yuya Kobayashi, Stephen E Lincoln,[...]. J Clin Oncol 2014
312
38

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Andrea Desmond, Allison W Kurian, Michele Gabree, Meredith A Mills, Michael J Anderson, Yuya Kobayashi, Nora Horick, Shan Yang, Kristen M Shannon, Nadine Tung,[...]. JAMA Oncol 2015
207
33

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
483
27

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Maren Weischer, Stig Egil Bojesen, Christina Ellervik, Anne Tybjaerg-Hansen, Børge Grønne Nordestgaard. J Clin Oncol 2008
184
27

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
27

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
27

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
27

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Hanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, Marijke Wasielewski, Anja de Snoo, Rogier Oldenburg, Antoinette Hollestelle, Mark Houben, Ellen Crepin, Monique van Veghel-Plandsoen,[...]. Nat Genet 2002
776
22

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
367
22

Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cezary Cybulski, Dominika Wokołorczyk, Anna Jakubowska, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bartłomiej Masojć, Tadeusz Deebniak, Bohdan Górski, Paweł Blecharz,[...]. J Clin Oncol 2011
130
22

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
22

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
665
22

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
22

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.
Anthony Renwick, Deborah Thompson, Sheila Seal, Patrick Kelly, Tasnim Chagtai, Munaza Ahmed, Bernard North, Hiran Jayatilake, Rita Barfoot, Katarina Spanova,[...]. Nat Genet 2006
473
22

Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Fergus J Couch, Katherine L Nathanson, Kenneth Offit. Science 2014
207
22

Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.
Jirina Bartkova, Johanna Tommiska, Lenka Oplustilova, Kirsimari Aaltonen, Anitta Tamminen, Tuomas Heikkinen, Martin Mistrik, Kristiina Aittomäki, Carl Blomqvist, Päivi Heikkilä,[...]. Mol Oncol 2008
115
16

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E Garber, Christina Herold, Leif Ellisen,[...]. Cancer 2015
259
16

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, William D Foulkes, Marc Tischkowitz. N Engl J Med 2014
39
16


Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
16

Multigene Panel Testing in Oncology Practice: How Should We Respond?
Allison W Kurian, James M Ford. JAMA Oncol 2015
44
16

Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Cornelia Kraus, Juliane Hoyer, Georgia Vasileiou, Marius Wunderle, Michael P Lux, Peter A Fasching, Mandy Krumbiegel, Steffen Uebe, Miriam Reuter, Matthias W Beckmann,[...]. Int J Cancer 2017
62
16

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
Tom Walsh, Ming K Lee, Silvia Casadei, Anne M Thornton, Sunday M Stray, Christopher Pennil, Alex S Nord, Jessica B Mandell, Elizabeth M Swisher, Mary-Claire King. Proc Natl Acad Sci U S A 2010
328
16

Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
Francisco Javier Gracia-Aznarez, Victoria Fernandez, Guillermo Pita, Paolo Peterlongo, Orlando Dominguez, Miguel de la Hoya, Mercedes Duran, Ana Osorio, Leticia Moreno, Anna Gonzalez-Neira,[...]. PLoS One 2013
70
16

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
16

Hereditary breast and ovarian cancer: new genes in confined pathways.
Finn Cilius Nielsen, Thomas van Overeem Hansen, Claus Storgaard Sørensen. Nat Rev Cancer 2016
186
16

Hereditary breast cancer: the era of new susceptibility genes.
Paraskevi Apostolou, Florentia Fostira. Biomed Res Int 2013
141
16

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
16

General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles.
Claire Julian-Reynier, Anne-Deborah Bouhnik, D Gareth Evans, Hilary Harris, Christi J van Asperen, Aad Tibben, Joerg Schmidtke, Irmgard Nippert. BMC Cancer 2015
5
60


International Variation in Female Breast Cancer Incidence and Mortality Rates.
Carol E DeSantis, Freddie Bray, Jacques Ferlay, Joannie Lortet-Tieulent, Benjamin O Anderson, Ahmedin Jemal. Cancer Epidemiol Biomarkers Prev 2015
299
16

Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Andrew J Lee, Alex P Cunningham, Marc Tischkowitz, Jacques Simard, Paul D Pharoah, Douglas F Easton, Antonis C Antoniou. Genet Med 2016
46
16

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
A J Lee, A P Cunningham, K B Kuchenbaecker, N Mavaddat, D F Easton, A C Antoniou. Br J Cancer 2014
134
16

Counselling framework for moderate-penetrance cancer-susceptibility mutations.
Nadine Tung, Susan M Domchek, Zsofia Stadler, Katherine L Nathanson, Fergus Couch, Judy E Garber, Kenneth Offit, Mark E Robson. Nat Rev Clin Oncol 2016
164
16

Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
Monica Marabelli, Su-Chun Cheng, Giovanni Parmigiani. Genet Epidemiol 2016
52
16

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Andrew Lee, Nasim Mavaddat, Amber N Wilcox, Alex P Cunningham, Tim Carver, Simon Hartley, Chantal Babb de Villiers, Angel Izquierdo, Jacques Simard, Marjanka K Schmidt,[...]. Genet Med 2019
143
16

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Nazneen Rahman, Sheila Seal, Deborah Thompson, Patrick Kelly, Anthony Renwick, Anna Elliott, Sarah Reid, Katarina Spanova, Rita Barfoot, Tasnim Chagtai,[...]. Nat Genet 2007
657
11

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Ella R Thompson, Simone M Rowley, Na Li, Simone McInerny, Lisa Devereux, Michelle W Wong-Brown, Alison H Trainer, Gillian Mitchell, Rodney J Scott, Paul A James,[...]. J Clin Oncol 2016
113
11



A method and server for predicting damaging missense mutations.
Ivan A Adzhubei, Steffen Schmidt, Leonid Peshkin, Vasily E Ramensky, Anna Gerasimova, Peer Bork, Alexey S Kondrashov, Shamil R Sunyaev. Nat Methods 2010
11

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Bing Xia, Qing Sheng, Koji Nakanishi, Akihiro Ohashi, Jianmin Wu, Nicole Christ, Xinggang Liu, Maria Jasin, Fergus J Couch, David M Livingston. Mol Cell 2006
545
11

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
Michael J Hall, Julia E Reid, Lynn A Burbidge, Dmitry Pruss, Amie M Deffenbaugh, Cynthia Frye, Richard J Wenstrup, Brian E Ward, Thomas A Scholl, Walter W Noll. Cancer 2009
227
11

Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
T H Thai, F Du, J T Tsan, Y Jin, A Phung, M A Spillman, H F Massa, C Y Muller, R Ashfaq, J M Mathis,[...]. Hum Mol Genet 1998
141
11

Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Magdalena Ratajska, Ewelina Antoszewska, Anna Piskorz, Izabela Brozek, Åke Borg, Hanna Kusmierek, Wojciech Biernat, Janusz Limon. Breast Cancer Res Treat 2012
63
11

Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
L C Wu, Z W Wang, J T Tsan, M A Spillman, A Phung, X L Xu, M C Yang, L Y Hwang, A M Bowcock, R Baer. Nat Genet 1996
567
11

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
215
11

ACR Appropriateness Criteria Breast Cancer Screening.
Martha B Mainiero, Ana Lourenco, Mary C Mahoney, Mary S Newell, Lisa Bailey, Lora D Barke, Carl D'Orsi, Jennifer A Harvey, Mary K Hayes, Phan Tuong Huynh,[...]. J Am Coll Radiol 2013
108
11

Online tool to guide decisions for BRCA1/2 mutation carriers.
Allison W Kurian, Diego F Munoz, Peter Rust, Elizabeth A Schackmann, Michael Smith, Lauren Clarke, Meredith A Mills, Sylvia K Plevritis. J Clin Oncol 2012
57
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.